💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Idursulfase

CHEMBL1201826 Phase 4 승인됨 Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This enzyme replacement therapy is used to treat mucopolysaccharidosis type II (Hunter syndrome), a rare genetic disorder caused by deficiency of the enzyme iduronate-2-sulfatase. Without this enzyme, glycosaminoglycans accumulate in cells throughout the body, causing progressive damage to multiple organ systems. Regular intravenous infusions help slow disease progression.

작용 기전

Provides exogenous replacement of the deficient or absent enzyme, enabling the metabolic processing of accumulated substrates and restoring normal metabolic function.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Provides exogenous replacement of the deficient or absent enzyme, enabling the metabolic processing of accumulated substrates and restoring normal metabolic function.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This enzyme replacement therapy is used to treat mucopolysaccharidosis type II (Hunter syndrome), a rare genetic disorder caused by deficiency of the enzyme iduronate-2-sulfatase. Without this enzyme, glycosaminoglycans accumulate in cells throughout the body, causing progressive damage to multiple organ systems. Regular intravenous infusions help slow disease progression.

Provides exogenous replacement of the deficient or absent enzyme, enabling the metabolic processing of accumulated substrates and restoring normal metabolic function.

Yes, Idursulfase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201826. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.